IGF2BP3抗体;IGF2BP3 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using IGF2BP3 mouse mAb against Hela (1), Jurkat (2), NIH/3T3 (3), COS7 (4), HepG2 (5), K562 (6), A549 (7), and HEK293 (8) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of Hela cells using IGF2BP3 mouse mAb (green) and negative control (red).    

  
  

IGF2BP3 (Insulin-like Growth Factor 2 mRNA-Binding Protein 3), also known as IMP3 or KOC, is a member of the conserved IGF2BP family of RNA-binding proteins that regulate mRNA stability, localization, and translation. It is characterized by four KH domains and two RRM domains, enabling interactions with target mRNAs, including IGF2. MYC, and ACTB. While IGF2BP3 is predominantly expressed during embryogenesis, its re-expression in adult tissues is strongly linked to carcinogenesis. Overexpression of IGF2BP3 has been observed in various malignancies, including pancreatic, liver, colorectal, and ovarian cancers, where it promotes tumor progression by enhancing cell proliferation, invasion, and metastasis through post-transcriptional regulation of oncogenic mRNAs.

Antibodies targeting IGF2BP3 are critical tools for studying its expression patterns and functional roles. These antibodies are widely used in techniques like immunohistochemistry (IHC), immunofluorescence (IF), and Western blotting to detect IGF2BP3 protein levels in clinical samples or experimental models. Commercially available clones (e.g., mouse monoclonal antibody 67.9) are frequently validated for specificity using knockdown/knockout cell lines or tissues lacking IGF2BP3 expression. Due to high homology among IGF2BP family members (IGF2BP1-3), rigorous validation is essential to avoid cross-reactivity. Clinically, IGF2BP3 antibodies aid in cancer diagnosis and prognosis, as its overexpression often correlates with aggressive tumor behavior and poor patient outcomes. However, standardization challenges persist in interpreting staining results across different cancer types and antibody batches. Research applications also extend to exploring IGF2BP3 as a therapeutic target or biomarker in liquid biopsies.